Renhaim Inc. is currently researching and developing the DMOAD osteoarthritis ‘RTX-V002’ and Idiotype cancer vaccine ‘RTX-V002’ using mRNA technology. In addition to these pipelines, Renhaim has in-licensed a cell-therapy (BAFFR CAR-T) from PeproMene Bio, Inc. with an exclusive right to develop, manufature, and commercialize in Korea region. We plan to conduct and complete a Phase II clinical trial for BAFFR CAR-T by 2028, then followed by NDA (new drug application) submission to the Ministry of Food and Drug Safety (MFDS).

For more details, please refer to the link below.